Evidence map›Paper›PMID 38560722›Full record

ArticleThe journal of allergy and clinical immunology. Global2024

Ustekinumab for pyoderma gangrenosum-like skin ulcerations in late-onset leukocyte adhesion deficiency.

Florian Schmid, Kerstin Kerl-French, Barbara Meier-Schiesser, Kai Lehmberg, Peter H Hoeger

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of allergy and clinical immunology. Global, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Florian SchmidDepartment of Pediatrics, Catholic Children's Hospital Wilhelmstift, Hamburg, Germany.
Kerstin Kerl-FrenchDepartment of Dermatology, University of Zurich, Zurich, Switzerland.
Barbara Meier-SchiesserDepartment of Dermatology, University of Zurich, Zurich, Switzerland.
Kai LehmbergDepartment of Pediatric Haematology and Oncology, University of Hamburg, Hamburg, Germany.
Peter H HoegerDepartment of Pediatrics, Catholic Children's Hospital Wilhelmstift, Hamburg, Germany.
Katholisches Kinderkrankenhaus Wilhelmstift · DEUniversity of Zurich · CHUniversität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Leukocyte adhesion deficiency type 1 (LAD-1) is a congenital immunodeficiency leading to impaired trafficking of neutrophils to inflammation sites. Solitary or multiple pyoderma gangrenosum (PG)-like skin ulcers (PGLUs) have been reported previously in 13 children (aged 0.5-19 years) with LAD-1. Objective: Our aim was to report the case of a 10-year-old boy presenting with PGLUs as the first manifestation of LAD-1 treated with ustekinumab. Methods: We obtained Results: PGLUs were triggered by cutaneous ringworm infection ( Conclusions: PGLUs, triggered by ringworm infection, can be a late harbinger of LAD-1. Ustekinumab is a safe and effective therapeutic option for patients with LAD-1 and PGLUs while bridging the time until stem cell transplantation.

Indexed as

in situ cytokine profilesLeukocyte adhesion deficiencypyoderma gangrenosum–like ulcersustekinumab therapy

Identifiers

PMID38560722
PMCPMC10981098
OpenAlexW4392287783

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.